14 recruiting, 11 active not recruiting, 7 completed, 6 unknown. 25 Phase 2, 9 Phase 1, 5 Phase 3, 2 Not applicable, 2 Phase 4.
Follow Extensive-stage Small-cell Lung Cancer: new trials by email Literature Review of Extensive-stage Small-cell Lung Cancer trials Research Report on Extensive-stage Small-cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer | Phase 1 | Suspended | University of Maryland, Baltimore | 50 | 2027-01-30 | 2026-09-14 |
| A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC Lurbinectedin, Durvalumab - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Jazz Pharmaceuticals | 50 | 2026-11-30 | 2026-09-17 |
| A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer BL-M14D1, Atezolizumab - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 36 | 2026-07-09 | 2026-08-25 |
| A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) BL-B01D1, Tislelizumab, Carboplatin - Extensive-stage Small-cell Lung Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 562 | 2026-06-15 | 2026-10-28 |
| Prospective Observational Study on ES-SCLC Standard of Care Anti-tumor Therapy - Extensive-stage Small-cell Lung Cancer, Small Cell Lung Cancer | Not yet recruiting | Peking Union Medical College Hospital | 96 | 2025-09-01 | 2025-09-15 | |
| Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer Tafolecimab, Sintilimab (approved), Etoposide - Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 40 | 2025-07-30 | 2026-09-15 |
| Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC Extensive-stage Small-cell Lung Cancer | Recruiting | Henan Cancer Hospital | 40 | 2025-02-20 | 2025-11-24 | |
| Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer Pumitamig, Atezolizumab, Etoposide - Extensive-stage Small-cell Lung Cancer | Phase 3 | Recruiting | BioNTech SE | 621 | 2025-02-03 | 2026-10-14 |
| A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer Valemetostat, Atezolizumab - Extensive-stage Small-cell Lung Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 24 | 2025-01-29 | 2026-08-11 |
| Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC Low-dose radiotherapy, Tifcemalimab injection, Toripalimab - Extensive-stage Small-cell Lung Cancer | Phase 1 | Withdrawn | Sichuan University | 2025-01-10 | 2026-04-29 | |
| An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer Radioconjugate, Positron Emission Tomography, Computed Tomography - Extensive-stage Small-cell Lung Cancer, Limited-stage Small-cell Lung Cancer | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2024-10-01 | 2024-09-27 | |
| Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases Bevacizumab - Extensive-stage Small-cell Lung Cancer, Liver Metastases | Phase 2 | Recruiting | Kamya Sankar | 39 | 2024-08-11 | 2026-10-08 |
| Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide - Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer | Phase 2 | Active not recruiting | BioNTech SE | 110 | 2024-08-05 | 2026-09-14 |
| Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC Tislelizumab, Etoposide, Carboplatin or Cisplatin - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Second Hospital of Shanxi Medical University | 40 | 2024-08-01 | 2026-04-24 |
| A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer BL-B01D1, PD-1 monoclonal antibody - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 66 | 2024-06-13 | 2026-07-23 |
| Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab Tarlatamab, Durvalumab - Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer | Phase 3 | Active not recruiting | Amgen | 563 | 2024-06-05 | 2025-12-17 |
| Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC Low-dose radiotherapy, Etoposide, Cisplatin - Lung Cancer, Extensive-stage Small-cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Sichuan University | 45 | 2024-04-18 | 2026-05-05 |
| MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer MGC018 - Extensive-stage Small-cell Lung Cancer | Phase 2 | Active not recruiting | Georgetown University | 9 | 2024-04-15 | 2026-06-25 |
| Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy Adebrelimab, Irinotecan Liposome (II), Adebrelimab, Irinotecan Liposome (II), Famitinib - Extensive-stage Small-cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Baohui Han | 80 | 2024-04-01 | 2024-03-27 |
| A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC. adebrelimab, famitinib, chemotherapy - Extensive-stage Small-cell Lung Cancer | Phase 2 | Not yet recruiting | Harbin Medical University | 40 | 2024-03-15 | 2024-03-12 |
Showing 20 of 46. Sign in to see all of them.
Small Cell Lung Carcinoma (46) · Lung Neoplasms (7) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Fallopian Tube Neoplasms (1) · Neuroendocrine Tumors (1)
Bronchial Neoplasms (46) · Carcinoma, Bronchogenic (46) · Lung Diseases (46) · Neoplasms (46) · Neoplasms by Site (46) · Respiratory Tract Diseases (46) · Respiratory Tract Neoplasms (46) · Thoracic Neoplasms (46) · Lung Neoplasms (39) · Adenocarcinoma (1) · Adnexal Diseases (1) · Breast Diseases (1) · Carcinoma (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1)
Carboplatin (18) · Etoposide (18) · Cisplatin (10) · durvalumab (10) · Radiotherapy (4) · Drug Therapy (3) · atezolizumab (3) · trilaciclib (3) · PM 01183 (2) · Platinum (2) · Radiosurgery (2) · Topotecan (2) · famitinib (2) · tislelizumab (2) · ADP Ribose Transferases (1)
Sichuan Baili Pharmaceutical Co., Ltd. (3) · Sichuan University (3) · Amgen (2) · BioNTech SE (2) · Henan Cancer Hospital (2) · Jazz Pharmaceuticals (2) · Jiangsu Simcere Pharmaceutical Co., Ltd. (2) · 23andMe, Inc. (1) · Affiliated Cancer Hospital & Institute of Guangzhou Medical University (1) · AstraZeneca (1) · Baohui Han (1) · Beijing Chest Hospital (1) · Chinese Academy of Medical Sciences (1) · Daiichi Sankyo (1) · European Organisation for Research and Treatment of Cancer - EORTC (1)
China (22) · United States (13) · France (5) · Spain (5) · Australia (4) · Canada (4) · Germany (4) · Poland (4) · South Korea (4) · Italy (3) · Japan (3) · Netherlands (3) · Turkey (Türkiye) (3) · United Kingdom (3) · Austria (2)
You Lu, MD (3) · Antonin Levy, MD (1) · Bi Nan, MD (1) · Caicun Zhou, PHD (1) · Chen Li Juan, Prof (1) · Christine Bestvina, MD (1) · Chul Kim, MD (1) · Corinne Faivre-Finn, MD (1) · Eric Hau (1) · Gang Jin, Dr. (1) · Grace Dy, MD (1) · Helena Linardou, MD (1)
PMID 35526266, PMID 37020926, PMID 39185596, PMID 39651931, PMID 39800716, PMID 40623886, PMID 40934933, PMID 41086386
2023 (1), 2025 (1)